A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Conditions

• Chronic Migraine

Eligibility Criteria

Sex

ALL

Age

12 Years - 17 Years

Healthy Volunteers

Not accepted

Interventions

• Atogepant — DRUG
  Oral tablet
• Placebo for Atogepant — DRUG
  Oral tablet

Study Details

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world. Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks. Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.

Key Dates

Start date

Feb 13, 2025

Status verified

Jun 2026

Primary completion

Mar 31, 2031

Completion

Mar 31, 2031

Study Design

Enrollment

420 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Atogepant
  Participants will receive atogepant once daily for 12 weeks.
• Placebo Comparator: Placebo for Atogepant
  Participants will receive placebo for atogepant once daily for 12 weeks.

Primary Outcome Measure

Number of Participants Experiencing Adverse Events (AEs) [ Time Frame: Up to approximately 16 weeks ]

Central Contacts

• ABBVIE CALL CENTER
  844-663-3742
  [email protected]

Locations (31)

Find similar trials in Huntsville, AL

Related Studies

• Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics
  Recruiting · Stanford University · Stanford, California
• BOTOX® vs. XEOMIN® for Chronic Migraine
  PHASE3 · Recruiting · Naval Medical Center Camp Lejeune · Jacksonville, North Carolina
• Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
  Recruiting · University of Michigan · Ann Arbor, Michigan
• Responding With Evidence and Access for Childhood Headaches
  Recruiting · Children's Hospital Medical Center, Cincinnati · Birmingham, Alabama